SCHEMBL12199731

SCHEMBL12199731

O=C1NC(=O)C2(CCc3ccc([N+](=O)[O-])cc3CC2)N1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 1/20 0.51
PNMT P11086 4/20 0.48
ADRA2A P08913 2/20 0.48
TDP2 O95551 1/20 0.46
AKR1B1 P15121 2/20 0.45
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
GRIN2B Q13224 3/20 0.41
HTT P42858 1/20 0.40
CAPN9 O14815 1/20 0.39
CASP3 P42574 1/20 0.39
CYP3A4 P08684 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.39
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
TLR9 Q9NR96 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379349 0.83 TDP2 (0.48) CRBNPNMTADRA2ATDP2AKR1B1
SCHEMBL12199728 0.77 TSHR (0.42) CRBNAKR1B1GRIN2BTDP1MEN1
SCHEMBL16659357 0.77 TSHR (0.42) CRBNPNMTADRA2ATDP2AKR1B1
SCHEMBL12199729 0.75 TSHR (0.57) CRBNAKR1B1TDP1MAPT
SCHEMBL9483063 0.75 PNMT (0.65) PNMTADRA2ATDP2ADRA2BADRA2C
SCHEMBL30709850 0.75 PNMT (0.65) PNMTADRA2ATDP2ADRA2BADRA2C
SCHEMBL2061978 0.74 PNMT (0.53) PNMTADRA2ATDP2ADRA2BADRA2C
SCHEMBL16659358 0.73 ALDH1A1 (0.53) CRBNTDP2TDP1MEN1MAPT
SCHEMBL16659373 0.72 CRBN (0.45) CRBNTDP1MAPTRAB9A
SCHEMBL21484128 0.72 CRBN (0.67) CRBNMEN1LMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296750-B2 Spirolactam CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2016-03-29 US disclosed
US-20150111914-A1 SPIROLACTAM CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2015-04-23 US disclosed
US-20110245240-A1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245240-A1 CGRP RECEPTOR ANTAGONISTS CCKAR, CALCRL, QRFPR CRBN 3154/4885PNMT 2414/4885ADRA2A 54/4885
US-20150111914-A1 SPIROLACTAM CGRP RECEPTOR ANTAGONISTS CALCRL, CALCR, TACR1 CRBN 3488/4885PNMT 2396/4885ADRA2A 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.